MedTrace Logo

Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa

NCT01090908 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-11-22

No results posted yet for this study

Summary

This is a Phase 1/2a, multicenter study, designed to evaluate the pharmacokinetics, safety, and tolerability of once daily administration of 150 mg of Ciprofloxacin for Inhalation (CFI) in patients with Cystic Fibrosis who have a history of chronic P. aeruginosa lung infection.

Conditions

Interventions

DRUG

Antibiotic

Sponsors & Collaborators

  • Aradigm Corporation

    lead INDUSTRY

Principal Investigators

  • P Bruinenber, MD · Aradigm Corporation

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-03-31
Completion
2011-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01090908 on ClinicalTrials.gov